Fractyl Health (NASDAQ:GUTS) Stock Gets Price Target Trim from Morgan Stanley

Fractyl Health (NASDAQ:GUTS) had its price target decreased by investment analysts at Morgan Stanley to $4.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 182.69% from the company’s current price.

A number of other brokerages have also recently commented on GUTS. Wall Street Zen cut shares of Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Craig Hallum set a $5.00 target price on shares of Fractyl Health in a research report on Monday. Finally, Weiss Ratings cut shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $50.25.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS traded down $0.14 during trading on Monday, reaching $1.42. The stock had a trading volume of 1,072,092 shares, compared to its average volume of 330,205. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. Fractyl Health has a 1-year low of $1.37 and a 1-year high of $29.34. The stock has a market cap of $18.76 million, a PE ratio of -0.13 and a beta of 2.42. The business has a fifty day moving average price of $6.89 and a 200-day moving average price of $8.06.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.44) EPS for the quarter, beating the consensus estimate of ($1.62) by $0.18. On average, equities analysts forecast that Fractyl Health will post -6.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC purchased a new position in shares of Fractyl Health during the 2nd quarter worth approximately $8,968,058. General Catalyst Group Management LLC purchased a new stake in Fractyl Health during the 2nd quarter worth about $3,880,000. Bank of America Corp DE purchased a new position in Fractyl Health in the second quarter worth approximately $4,791,000. Sanctuary Advisors LLC purchased a new position in Fractyl Health in the second quarter valued at $26,000. Finally, PEAK6 LLC purchased a new position in Fractyl Health in the second quarter valued at $159,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.